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Background: Gallbladder (GB) polyps and ischaemic heart disease (IHD) share some
common risk factors. We investigated the longitudinal effects of gallbladder (GB) polyps,
as a surrogate metabolic indicator, on IHD.
Methods: We enrolled 19,612 participants from the health risk assessment study
(HERAS) and Korean Health Insurance Review and Assessment Service (HIRA) database.
The primary outcome was IHD, which consisted of angina pectoris (ICD-10 code I20)
or acute myocardial infarction (ICD-10 code I21) that occurred after enrolment into the
study. We calculated hazard ratios (HRs) with 95% confidence intervals (CIs) for IHD
according to the presence of GB polyps using multivariate Cox proportional hazards
regression models.
Results: The median follow-up period was 29.9 months and a total of 473 individuals
(2.4%, 473/19,612) developed IHD. Individuals with GB polyps had an increased risk of
IHD compared with the control group after adjusting for potential confounding variables
(HR = 1.425; 95% CI, 1.028–1.975). Furthermore, the coexistence of hypertension or
dyslipidaemia resulted in an increased risk (HR= 2.14, 95% CI, 1.34–3.44 or HR= 2.09,
95% CI, 1.32–3.31, respectively) of new-onset IHD in the GB polyp group.
Conclusions: GB polyps was an independent risk factor of IHD. Awareness of these
associations will inform clinicians on the need to include cardiovascular risk management
as part of the routine management of patients with GB polyps.
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INTRODUCTION
Ischaemic heart disease (IHD) is the leading cause of morbidity and mortality among middle-aged
and older individuals globally (1). The incidence of cardiovascular disease (CVD) has increased in
developed Asian countries because life style and eating habits have becomemore westernized (2, 3).
Also, IHD carries the 2nd leading death rate following cancer in South Korea, while the recent trend
has been gradually rising over the last decade (4). Therefore, it is crucial for physicians to assess the
presence of IHD-related risk factors for early prevention of IHD (5).
Gallbladder (GB) polyps are defined based on the presence of polypoidal lesions in the GB
mucosa, and ultrasonography (USG) is generally used in clinical settings to detect these polyps
(6). USG is a non-invasive tool with >90% sensitivity and specificity for diagnosing GB polyps (7).
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The prevalence of GB polyps in Korea is estimated at 2.2–
8.5%, which is higher than that for Western countries but
lower than the prevalence in China (8–10). Although, most GB
polyps are cholesterol polyps and benign lesions, the presence
of GB polyps is used for the early detection of malignancy
and to determine the appropriate time to undergo GB resection
surgery (11).
Previous studies suggested that the presence of GB polyps is
closely associated with insulin resistance, obesity, and CVD (12,
13). Hence, GB polyps and IHD may share common risk factors;
however, few studies have explored the relationship between
these two conditions (14).
FIGURE 1 | Flowchart for the selection of study participants.
We conducted a regional and community-based cohort study
to investigate the association between GB polyps found by USG
and the development of IHD. We included data from the health
risk assessment study (HERAS) and Korea Health Insurance
Review and Assessment Service (HIRA) database.
MATERIALS AND METHODS
Data and Study Cohort
This retrospective study was derived from the HERAS, which has
been previously described in details on design and methodology
(15). In brief, the cohort consisted of 20,530 sequential subjects
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TABLE 1 | Clinical and biochemical characteristics of the study population.
Total (n = 19,612) Controls (n = 18,413) Gallbladder polyp (n = 1,119) P-valuea
Age, years 45.7 ± 10.9 45.7 ± 10.8 46.8 ± 10.7 <0.001
Male sex, % 52.4 51.9 59.0 <0.001
Body mass index, kg/m2 23.4 ± 3.1 23.4 ± 3.1 23.4 ± 3.0 0.939
Systolic blood pressure, mmHg 122.4 ± 15.7 122.4 ± 15.7 122.6 ± 15.5 0.674
Diastolic blood pressure, mmHg 76.3 ± 10.2 76.3 ± 10.2 76.5 ± 10.0 0.668
Mean arterial pressure, mmHg 91.7 ± 11.6 91.7 ± 11.7 91.8 ± 11.4 0.661
Fasting plasma glucose, mg/dL 94.4 ± 18.9 94.3 ± 19.0 95.1 ± 18.4 0.145
Total cholesterol, mg/dL 189.3 ± 34.1 189.3 ± 34.1 190.3 ± 34.2 0.325
Triglyceride, mg/dL 126.3 ± 90.9 126.4 ± 89.8 125.2 ± 106.7 0.715
HDL-cholesterol, mg/dL 53.2 ± 12.7 53.2 ± 12.8 52.0 ± 12.1 <0.001
Aspartate aminotransferase, IU/L 21.9 ± 12.1 21.9 ± 12.3 21.0 ± 8.6 <0.001
Alanine aminotransferase, IU/L 23.3 ± 21.8 23.4 ± 22.1 22.2 ± 15.7 0.015
γ-glutamyltransferase, IU/L 32.3 ± 40.8 32.3 ± 41.3 32.2 ± 31.8 0.894
C-reactive protein, mg/L 1.1 ± 1.4 1.1 ± 1.4 1.0 ± 1.2 0.104
Current smoker, % 24.6 24.6 25.0 0.009
Alcohol drinking, % 43.6 43.8 40.5 0.031
Regular exercise, % 31.7 31.6 33.2 0.270
Hypertension, % 23.2 23.2 24.0 0.495
Type 2 diabetes, % 5.3 5.3 5.1 0.773
Dyslipidaemia, % 38.7 38.8 38.2 0.693
Medication for comorbidities, %
Hypertension 10.1 10.0 12.3 0.008
Type 2 diabetes 3.0 2.9 3.6 0.176
Dyslipidaemia 3.0 3.0 2.6 0.403
Impaired fasting glucose, % 16.9 16.7 19.9 0.004
aP-values were calculated using t-test (age, body mass index, systolic blood pressure, diastolic blood pressure, mean arterial pressure, fasting plasma glucose, total cholesterol,
triglyceride, HDL-cholesterol, aspartate aminotransferase, alanine aminotransferase, γ-glutamyltransferase, and C-reactive protein) or the chi-squared test (sex, current smoker, alcohol
drinking, regular exercise, hypertension, type 2 diabetes, dyslipidaemia, and impaired fasting glucose).
HDL, high density-lipoprotein cholesterol.
who visited the Health Promotion Center at the Yonsei
University Gangnam Severance Hospital for health examinations
between November 2006 and June 2010. We excluded 528
participants who had previously been diagnosed with IHD or
ischaemic stroke. In addition, patients who met at least one of
the following criteria were excluded: <20 years of age, missing
data, or high-sensitivity C-reactive protein (hsCRP) levels ≥
10 mg/L (n = 390). Informed consent was obtained from
each participant.
Each participant completed a questionnaire that described
lifestyle and medical history. The questionnaire on smoking
status consists of the following categories: never smoked, current
smoker, and former smoker. A regular alcohol drinker was
defined as a person who consumed more than 140 g of alcohol
per week. Regular exercise was defined as moderate physical
activity three or more times per week. Body weight and height
were measured to the nearest 0.1 kg and 0.1 cm, respectively, in
light indoor clothing without footwear. Body mass index (BMI)
was calculated as weight divided by height squared (kg/m2).
Systolic blood pressure (SBP) and diastolic blood pressure (DBP)
were measured in the sitting position after 10min of rest using
a standard mercury sphygmomanometer (Baumanometer, W.A.
TABLE 2 | Overall incidence of ischaemic heart disease according to the
presence of gallbladder polyp.
Controls Gallbladder polyp
New cases of ischaemic heart disease, n 430 43
Mean follow-up, years 2.4 ± 1.1 2.2 ± 1.2
Pearson-years of follow-up 43,539 2,613
Incidence rate/1,000 person-years 9.9 16.5
Baum Co Inc., Copiague, NY, USA). Mean arterial pressure was
calculated from SBP and DBP. Dyslipidaemia was defined as
total cholesterol ≥ 240 mg/dL, triglycerides ≥ 150 mg/dL, high
density-lipoprotein (HDL) cholesterol < 40 mg/dL for men and
< 50 mg/dL for women, or the use of lipid-lowering medication.
Diabetes was defined as a fasting plasma glucose (FPG) greater or
equal to 126 mg/dL, a self-reported history of diabetes, or current
use of diabetes medication. Among individuals without diabetes,
impaired fasting glucose was defined as FPG levels between 100
and 126 mg/dL.
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Exposures and Outcomes
Experienced radiologists performed abdominal USG using a 3.5-
MHz transducer (HDI 5000, Philips, Bothell, WA, USA) and
were blinded to laboratory and clinical data. GB polyps were
assessed by well-described radiological criteria. A GB polyp was
diagnosed if ultrasonography showed any size of hyperechoic
mass protruding from the GB wall, and there was no acoustic
shadowing or movement with a postural change. The control
group without GB polyps consisted of 18,413 participants, and
the GB polyp group comprised 1,119 patients. The primary
outcome, previously described, was IHD, which consisted of
angina pectoris (ICD-10 code I20) or acute myocardial infarction
(ICD-10 code I21) that occurred after enrolment into the study
(15). To define baseline and post-survey outcomes, we linked a
personal 13-digit identification number that was assigned to each
participant by the Korean HIRA between November 1, 2006 and
December 31, 2010.
Statistical Analysis
We compared the baseline characteristics according to the
presence of GB polyps using Student’s t-tests for continuous
variables and chi-squared tests for categorical variables. We
have used box plots and the Kolmogorov-Smirnov test to
evaluate the distribution of the variables. Adjusted survival
curves were used to estimate the cumulative incidence of
IHD for each group. Using the Cox proportional hazards
regression model, we calculated hazard ratios (HRs) and 95 %
confidence intervals (CIs) for new-onset IHD after adjusting
for potential confounding variables. Furthermore, we evaluated
whether the presence of GB polyps affected the incidence
of IHD when combined with metabolic comorbidities. All
analyses were performed using SAS version 9.4 software
(SAS Institute Inc., Cary, NC, USA). All statistical tests were
two-sided, and statistical significance was set at P < 0.05.
The data are presented as numbers ± standard deviation
or percentage.
RESULTS
A total of 19,612 participants (10,267 men and 9,345 women)
were included in the final analysis (Figure 1). Table 1 presents
the baseline characteristics of the HERAS-HIRA cohorts
according to the presence of GP polyps. There were no
differences in BMI, total cholesterol, FPG, TG, or hsCRP
between the two groups. The prevalence of comorbidities,
including hypertension, type 2 diabetes mellitus (T2DM),
and dyslipidaemia, was not significantly different between the
two groups.
Table 2 shows the incidence of and difference in IHD between
the control and GB polyp groups. A total of 473 individuals
(2.4%, 473/19,612) developed IHD during the follow-up and the
patients with GB polyps had a higher risk of developing IHD.
Furthermore, the GB polyp group showed a higher cumulative
incidence of IHD over 50 months after adjusting for age, sex,
hypertension, diabetes, and dyslipidaemia (P= 0.021) (Figure 2).
Table 3 presents the univariate and multivariate HRs of IHD
categorized by age, sex, alcohol intake, blood tests including
lipid profiles, and baseline comorbidities. The increase in
IHD risk in the multivariate model was dependent upon
greater age, male sex, increased BMI, total cholesterol, or
alanine aminotransferase, and GB polyps. Table 4 shows Cox
proportional hazard regression analyses for the risk of IHD
in patients with GB polyps in the presence of different
comorbidities. The coexistence of GB polyps and hypertension
or dyslipidaemia resulted in greater risk of IHD compared
with GB polyps alone. However, this cumulative effect was
observed only in patients with impaired FPG, not in participants
with diabetes.
FIGURE 2 | Cox regression survival curve. (A) unadjusted; (B) adjusted for age, sex, hypertension, diabetes, and dyslipidaemia.
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TABLE 3 | Univariate and multivariate Cox proportional-hazards regression models for incident ischaemic heart disease.
Univariate Multivariate
Variables HRs 95% CIs P-value HRs 95% CIs P-value
Age, years 1.071 1.063–1.080 <0.001 1.057 1.047–1.067 <0.001
Male sex, yes or no 1.759 1.453–2.130 <0.001 1.502 1.122–2.010 0.006
Body mass index, kg/m2 1.104 1.075–1.135 <0.001 1.046 1.011–1.083 0.010
Current smoking, yes or no 1.264 0.992–1.610 0.058 1.278 0.937–1.741 0.121
Alcohol drinking, yes or no 0.722 0.596–0.876 <0.001 0.766 0.618–0.949 0.014
Regular exercise, yes or no 1.599 1.325–1.930 <0.001 1.163 0.955–1.415 0.132
Mean arterial pressure, mmHg 1.023 1.016–1.031 <0.001 0.996 0.987–1.005 0.354
Fasting plasma glucose, mg/dL 1.011 1.008–1.013 <0.001 1.004 0.999–1.008 0.103
Total cholesterol, mg/dL 1.006 1.003–1.008 <0.001 1.003 1.001–1.006 0.018
Alanine aminotransferase, IU 1.003 1.002–1.004 <0.001 1.004 1.002–1.006 <0.001
C-reactive protein, mg/L 1.116 1.059–1.177 <0.001 1.004 0.939–1.074 0.904
Hypertension medication, yes or no 3.766 3.091–4.588 <0.001 1.714 1.350–2.175 <0.001
Diabetes medication, yes or no 3.163 2.288–4.373 <0.001 1.064 0.715–1.583 0.758
Dyslipidaemia medication, yes or no 4.139 3.103–5.521 <0.001 1.930 1.412–2.638 <0.001
Gallbladder polyp, yes or no 1.632 1.192–2.233 0.002 1.425 1.028–1.975 0.033
TABLE 4 | Hazard ratios and 95% confidence intervals for ischaemic heart disease according to gallbladder polyp in the context of metabolic diseases.
Model 1 Model 2
Comorbidities Controls GB polyp Controls GB polyp
HRs (95% CIs) P-value HRs (95% CIs) P-value HRs (95% CIs) P-value HRs (95% CIs) P-value
Hypertension
No 1.00 (reference) 1.44 (0.94–2.19) 0.090 1.00 (reference) 1.45 (0.93–2.24) 0.100
Yes 1.49 (1.22–1.83) <0.001 2.14 (1.34–3.44) 0.001 1.52 (1.23–1.88) <0.001 2.14 (1.32–3.48) 0.002
Type 2 diabetes
No 1.00 (reference) 1.49 (1.07–2.07) 0.018 1.00 (reference) 1.50 (1.06–2.11) 0.021
Yes 1.46 (1.09–1.94) 0.013 1.59 (0.59–4.26) 0.358 1.50 (1.12–2.02) 0.006 1.58 (0.59–4.23) 0.367
Dyslipidaemia
No 1.00 (reference) 1.51 (0.98–2.33) 0.059 1.00 (reference) 1.48 (0.94–2.32) 0.089
Yes 1.55 (1.28–1.87) <0.001 2.09 (1.32–3.31) 0.001 1.54 (1.26–1.88) <0.001 2.14 (1.33–3.43) 0.001
IFG
No 1.00 (reference) 1.42 (0.98–2.07) 0.066 1.00 (reference) 1.45 (0.98–2.13) 0.062
Yes 1.35 (1.07–1.70) 0.011 1.90 (1.08–3.32) 0.025 1.41 (1.11–1.80) 0.004 1.87 (1.04–3.35) 0.035
Model 1: adjusted for age and sex (+ diabetes if IFG).
Model 2: adjusted for age, sex, smoking status, alcohol intake, and physical activity (+ diabetes if IFG).
IFG, impaired fasting glucose.
DISCUSSION
We found that the presence of GB polyps alone was associated
with a 42.5% increase in the risk of developing IHD compared
with a non-polyp control group. By including IHD risk
factors, we discovered that the coexistence of hypertension or
dyslipidaemia resulted in an increased risk of IHD in the GB
polyp group by approximately 2-fold. However, this cumulative
effect was observed only in patients with impaired fasting blood
glucose, but not in those with type 2 diabetes mellitus, most of
whom are on glucose-lowering medications.
To our knowledge, only one other report has described
a relationship between GB polyps and CVD (13). However,
in this latter study, the authors did not fully assess IHD-
related risk factors to sufficiently show a causal relationship
between GB polyps and IHD. In our study, we evaluated
multiple risk factors that influence the development of
IHD, including blood glucose levels, lipid profiles, blood
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pressure, liver function, alcohol intake, smoking status,
and self-reported diseases, such as T2DM, hypertension,
and dyslipidaemia.
It is generally believed that GB disease is positively correlated
with metabolic syndrome, obesity, and T2DM because these
conditions share common risk factors, such as sedentary life
styles, dyslipidaemia, and fat rich diets (12, 16). Our results imply
that GB polyps are closely related to the development of IHD,
although this association may be an epiphenomenon and not
a causal effect. However, our findings suggest that GB polyps
may be a risk factor for IHD that is independent of traditional
risk factors.
In the present study, patients who presented with GB polyps
and the comorbidity hypertension or dyslipidaemia developed
an increased risk of IHD that was greater than patients with
GB polyps alone. This interaction was observed in patients with
impaired FPG, but not in those with T2DM. Considering that
the prevalence of metabolic diseases is not different between the
GB polyp group and controls at the baseline, both metabolic and
non-metabolic factors may contribute to the progression of IHD.
Epidemiological studies have reported that the development of
IHD is enhanced when CVD risk factors are combined with
obesity and metabolic syndrome, but not T2DM, in the general
population (17–20). This finding may be explained in part by the
medications used (e.g., metformin) and life style modifications
that may occur after a diagnosis of T2DM. Metformin has
been shown to protect the heart from fibrosis and remodeling
after myocardial infarction and decrease inflammation and
oxidative stress (21). As a result, patients with T2DM taking
metformin may have a weakened risk of developing IHD (22).
In addition, our study showed that hypertension had a more
obvious effect on IHD development than mean blood pressure at
the baseline assessment. Thismay be related to a follow-up period
of <5 years.
Recent epidemiological and experimental studies have
reported possible mechanisms by which GB polyps influence
the development of IHD. GB polyps are tumor or tumor-like
protrusions arising from the GB mucosa and are divided
into true polyps and pseudopolyps (23). True polyps are
classified as adenomas or adenocarcinomas, and pseudopolyps,
which represent over 90% of GB polyps, consist mainly of
cholesterol and inflammatory polyps (24, 25). As the names
suggest, the growth and development of the majority of GB
polyps are closely related with cholesterol metabolism and
inflammation (25). Acetyl-CoA acetyltransferase 2 (ACAT2)
is a key enzyme in the biogenesis of lipid bodies, which may
facilitate the pinocytosis of cholesterol and papillary hyperplasia
in the GB mucosa (26). Additionally, this enzyme decreases
GB contractility leading to cholesterol deposition in the GB
wall (27). ACAT2 is also responsible for incorporation of
cholesteryl ester in apoprotein B-containing lipoproteins
that leads to increased very low-density lipoprotein (VLDL)
secretion and coronary artery atherosclerosis (28). It has
been reported that inflammation is closely related to ACAT2
activity and downregulating ACAT2 is associated with lowering
cholesterol and preventing atherosclerosis (29). Collectively, the
interactive linkage between ACAT activity, inflammation, and
dyslipidaemia may have served as a shared mechanism for GB
polyps and IHD, an essential starting point for prevention and
treatment (30).
Previous cross-sectional studies have consistently found that
patients with metabolic syndrome have a high prevalence
of GB polyps, suggesting that insulin resistance may be a
potential cause (16, 31). An epidemiological study reported that
hyperinsulinemia increased the incidence of GB polyp in Korean
men (32). Therefore, we propose that screening patients with
GB polyps for metabolic disturbances will be important for early
detection and prevention of IHD.
The present study had several strengths. First, potential
IHD-related confounding factors were assessed by blood tests
along with traditional risk factors. Second, the identification
of GB polyps occurred during the process of screening
the general population rather than relying on the diagnosis
by doctors based on symptoms of GB disease. Also, we
minimized the misclassification of asymptomatic patients into
the control group in our study and decreased cohort bias.
USG by experienced radiologists has over 90% of accuracy for
the diagnosis of GB polyps (33, 34). Third, this study was
carried out using data from a large scale, cohort study to
ascertain IHD risk factors and included analyses of multiple
physiological tests.
Nevertheless, this study also has some limitations. For the
majority of patients with GB polyps, there was no information
regarding a pathological condition because the data were
obtained from asymptomatic patients who underwent health
check-ups. Additionally, this study was a retrospective cohort
study and USG was performed only at baseline. Therefore,
we were unable to discover new-onset GB polyps during the
follow-up period, which may have led to a selection bias.
The study cohort was composed of volunteers sequentially
visiting for health examination screenings conducted at a single
hospital; participants appeared healthier than most community-
based cohorts. The number of participants with both GB
polyps and comorbidities is small, 1.4% for hypertension, 0.3%
for diabetes, and 2.3% for dyslipidaemia. Further research
is needed on the risk of IHD according to GB polyps
in patients with each cardiometabolic comorbidity. Lastly,
individuals with diabetes may have been underestimated because
hemoglobin A1c and 2-h oral glucose tolerance tests were
not measured at the baseline. Despite these limitations, this
is the first study to assess a role for conventional IHD risk
factors in the association between GB polyps and development
of IHD.
CONCLUSIONS
This study showed that the presence of GB polyps is associated
with the development of IHD. Metabolic comorbidities are
significant factors that increase the risk of gallbladder polyps
associated with IHD. Also, early intervention of GB polyps may
reduce IHD risk. These findings may guide the prevention and
therapy of patients with both GB polyps and IHD and warrant
further studies on effective treatment options.
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